Overview

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Arrowhead Pharmaceuticals